Clinical trial NCT06137157: Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
Official title: A Randomized, Double-Blind, Vehicle-Controlled, First-in-Human Safety, Tolerability and Proof-of-Concept Study of Topical ATR12-351 in Adults With Netherton Syndrome
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Netherton Syndrome
Keywords: Ichthyosis
Netherton syndrome
Skin disease
ichthyosis linearis circumflexa
Lead sponsor: Azitra Inc.
Sponsor class: INDUSTRY
First posted: 2023-11-18
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Intrapatient, randomized controlled study: ATR12-351 will be applied to skin lesions on one side of the body, while the vehicle control will be applied to similar lesion on the other side of the body twice daily for 2 weeks. Each patient is randomized to receive ATR12-351 on either the left or right side.
Primary purpose: TREATMENT

Brief summary: The objectives of this clinical trial are to evaluate the safety and tolerability of topically applied ATR12-351, to understand what the body does to ATR12-351, and to observe treatment benefits of the drug in approximately 12 adult patients with Netherton Syndrome (NS). ATR12-351 will be applied to skin lesions on one side of the body, while the vehicle control will be applied to similar lesion on the other side of the body twice daily for 2 weeks.

Detailed description: Netherton syndrome (NS) is a rare but severe autosomal recessive disease that affects the skin, hair, and immune system. NS presents at birth with red skin covered by fine scales, a specific hair shaft abnormality ("bamboo hair"), atopic lesions, and elevated systemic immunoglobulin E (IgE) levels. Patients often develop allergies and asthma, and the unfortunate prognosis for infants with NS is poor, with 10% mortality in the first 6 months of life and recurrent infections. There are no FDA-approved treatment options for NS. NS is caused by mutations in in the SPINK5 gene encoding the serine protease inhibitor lymphoepithelial Kazal-type related inhibitor (LEKTI). Absence of LEKTI causes unregulated activity of proteases in the kallikrein subfamily, causing excessive desquamation of skin.

ATR12-351 is a topical ointment containing a lyophilized version of a live biotherapeutic product (LBP), Staphylococcus epidermidis (SE) strain designated SE351. This strain has been modified to be auxotrophic and to express recombinant human LEKTI protein (rhLEKTI). ATR12-351 is intended to address the underlying cause of NS by replacing deficient/dysfunctional LEKTI. The treatment consists of applying ATR12-351 to affected areas, where rhLEKTI produced by ATR12-351 will counter the dysregulated skin serine protease activity observed in NS patients.

This first-in-human study is a randomized, double-blind, vehicle-controlled clinical study to assess the safety, tolerability, and pharmacokinetics (PK) of topical ATR12-351 in approximately 12 adult Netherton syndrome patients who will serve as their own control. This study will include a 14-day treatment period to investigate the safety and tolerability of ATR12-351 applied to the skin and will be followed a total of 84 days for safety. The results of this first-in-human clinical study will establish safety and tolerability as well as initial efficacy of ATR12-351 application in Netherton syndrome patients.

Eligibility criteria: Inclusion Criteria:

* Adults ≥18 years of age
* Confirmed mutation of the serine protease inhibitor of Kazal type 5 (SPINK5) gene
* Involvement of ≥20% of body surface area with skin changes consistent with Netherton syndrome

Exclusion Criteria:

* Use of biologic therapies, antibiotics, antihistamines, corticosteroids, retinoids, disease-modifying antirheumatic drugs (DMARDs), immunosuppressive agents, phosphodiesterase-4 (PDE4) inhibitors, topical calcineurin inhibitors, or topical Janus kinase (JAK) inhibitors
* Open wounds or extensive areas of excoriation precluding identification of appropriate application sites in the Investigator's judgment
* Concurrent involvement in any other clinical study/expanded access program with an investigational drug or device or has participated in a clinical study within 30 days prior to the screening visit
* Residing with an immunocompromised person in the same dwelling from the baseline visit through 2 weeks after the treatment period
* History of ultraviolet phototherapy within the planned treatment area 4 weeks prior to baseline

Primary outcomes:
measure: Adverse events
timeFrame: 84 days
Secondary outcomes:
measure: Investigator's Global Assessment (IGA)
timeFrame: 42 days
measure: Patient's Global Assessment (PGA)
timeFrame: 42 days
measure: NS-modified SCORAD
timeFrame: 42 days
measure: Pharmacokinetics: plasma concentration
timeFrame: 42 days
measure: Pharmacokinetics: skin concentration (Cmax skin)
timeFrame: 42 days
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Stanford University
state: California
city: New Haven
country: United States
facility: Yale University
state: Connecticut
Study officials:
affiliation: Azitra Inc.
name: Mary Spellman, MD
role: STUDY_DIRECTOR
References: